Cybin Corp., a Canadian life sciences company focused on psychedelics and mushroom-psilocybin research, announced a new partnership with the Toronto Centre for Psychedelic Science.
With this partnership, the centers' co-founders, Rotem Petranker and Thomas Anderson will be appointed exclusive clinical advisors to Cybin.
"We feel many of the positive results that people have experienced with psychedelics require further scientific study with transparently-disclosed protocols and proper research study architecture to achieve repeatable results," Paul Glavine, CEO of Cybin Corp. told Benzinga. "Rotem and Thomas' commitment to open science echoes our philosophy. Together we expect to build a solid foundation and future for this industry, grounded in research and the scientific method."
Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science said, "We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development."
Related Links:
The Keys To Understanding Psilocybin's Medical Value, Market Potential
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.